The German biotech group that shot to global fame with the first authorized COVID-19 vaccine is now engineering its most radical transformation yet. BioNTech is simultaneously winding down its manufacturing footprint, preparing for the departure of its founding scientists, and betting billions on an oncology pipeline that will face its first major test later this month.
The company’s first-quarter results laid bare the financial strain of this transition. Revenue slumped to $138 million as pandemic-era demand evaporated, while the net loss ballooned to roughly $622 million, driven by heavy spending on cancer research. On an adjusted basis, the loss per share came in at $1.95 — slightly better than analysts had feared, but still a stark reminder of how far the business has shifted from its COVID heyday.
Investors have responded with caution. The stock, trading around €80, lost nearly 9% over the past week and sits roughly 20% below its 52-week high. At €81.00, the shares are just under their 50-day moving average, with a relative strength index of about 49 signaling a neutral market stance.
A Factory Network in Retreat
To free up capital for its oncology ambitions, BioNTech is dismantling much of its production infrastructure. Sites in Idar-Oberstein, Marburg, and Tübingen are slated for closure by the end of next year, while the company is also pulling out of a facility in Singapore. The German locations are expected to be wound down by the end of 2027, with the Singapore exit coming as early as the first quarter of that year. As many as 1,860 jobs are affected, and BioNTech is exploring partial or full sales of the plants.
Management expects these moves to generate annual savings of up to €500 million from 2029 onward — money that will be redirected into clinical development.
The Pipeline That Must Deliver
All eyes are on pumitamig (BNT327), the company’s most advanced oncology candidate. Developed in partnership with Bristol Myers Squibb, the drug combines PD-L1 checkpoint inhibition with VEGF-A neutralization. Five new registration trials kicked off in the first quarter alone, targeting breast, colorectal, gastric, and two types of lung cancer.
A fresh collaboration added momentum in April. BioNTech and Boehringer Ingelheim will test pumitamig alongside the T-cell engager obrixtamig in small-cell lung cancer, with Boehringer taking regulatory responsibility for the Phase 1b/2 study.
Should investors sell immediately? Or is it worth buying BioNTech?
The next crucial data point arrives at the ASCO congress, running from May 29 to June 2. BioNTech will present Phase 2 results from the ROSETTA-Lung-02 trial, which pits pumitamig plus chemotherapy against the established standard of pembrolizumab plus chemotherapy. How convincingly pumitamig performs in that head-to-head comparison will determine whether the stock gets its next catalyst.
Another candidate, gotistobart, showed early survival benefits in lung cancer at a recent medical conference, adding to the sense of momentum.
A Leadership Void Takes Shape
The May 15 virtual shareholder meeting will be pivotal. Investors are being asked to approve an expansion of the supervisory board from six to eight members, adding two specialists in clinical development who will oversee the search for successors to founders Ugur Sahin and Özlem Türeci.
The couple plans to exit BioNTech by the end of 2026 to build a new mRNA spin-off. Under the proposed arrangement, they would contribute relevant rights to the new entity, while BioNTech receives a minority stake and future milestone payments. A binding agreement is expected by the end of June.
Balance Sheet Backs the Bet
Despite the mounting losses, BioNTech’s financial position remains formidable. The company holds roughly $20 billion in cash and securities, or about €16.8 billion. Revenue guidance for 2026 stands at €2.0 billion to €2.3 billion, and a share buyback program of up to $1 billion has been announced.
Goldman Sachs and Wells Fargo both issued buy ratings on the stock this week, with Goldman estimating the addressable market for BioNTech’s oncology portfolio at over $100 billion. The analysts expect multiple important data readouts before year-end.
For now, the share price remains hostage to clinical outcomes. The ASCO presentation later this month will be the first major test of whether BioNTech’s oncology wager can succeed — and whether the market will reward a company that is shrinking its old identity to build a new one.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from May 7 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 7.
BioNTech: Buy or sell? Read more here...
